MPM Oncology Impact Management »

Dianthus Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Dianthus Therapeutics (DNTH) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Dianthus Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dianthus Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dianthus Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2026-03-31 $36M 424k 83.92

More positions owned by MPM Oncology Impact Management

DBV Technologies S A Sponsored Ads (DBVT)
Cullinan Therapeutics Common (CGEM)
Aktis Oncology Common
Liquidia Corporation Common (LQDA)
Alumis Common (ALMS)
Edgewise Therapeutics Common (EWTX)
Revolution Medicines Common (RVMD)
Agios Pharmaceuticals Common (AGIO)
Corcept Therapeutics Common (CORT)
Trevi Therapeutics Common (TRVI)
Dianthus Therapeutics Common (DNTH)
Xenon Pharmaceuticals Common (XENE)
MoonLake Immunotherapeutics Class A Ord (MLTX)
Travere Therapeutics Common (TVTX)
Evommune Common (EVMN)

View all positions for MPM Oncology Impact Management

Top funds holding Dianthus Therapeutics

FMR
BlackRock
RA Capital Management
Fairmount Funds Management
Wellington Management Company
Avidity Partners Management
Vanguard Group
Vanguard Capital Management
Octagon Capital Advisors
TCG Crossover Management
Citadel Advisors
State Street Corporation
VR Adviser
Fred Alger Management
Deerfield Management Company

View all funds holding Dianthus Therapeutics